SCHEMBL734900

SCHEMBL734900

COC(=O)[C@H](CC=O)N1CCN(c2ccc(OC(F)(F)F)cc2)CCC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 8/20 0.41
KCNA5 P22460 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
SCN9A Q15858 2/20 0.36
LIPE Q05469 1/20 0.36
CACNA1B Q00975 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM5 P08912 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734901 1.00 CHRM4 (0.41) CHRM4KCNA5L3MBTL1PPARDPPARA
SCHEMBL735360 0.90 NOTUM (0.41) CHRM4SCN9ALMNACHRM2CHRM1
SCHEMBL735359 0.90 NOTUM (0.41) CHRM4SCN9ALMNACHRM2CHRM1
SCHEMBL736074 0.88 LDHA (0.46) PPARDPPARALMNAMAPTHTT
SCHEMBL736073 0.88 LDHA (0.46) PPARDPPARALMNAMAPTHTT
SCHEMBL735690 0.87 CHRM4 (0.41) CHRM4KCNA5L3MBTL1PPARDPPARA
SCHEMBL735691 0.87 CHRM4 (0.41) CHRM4KCNA5L3MBTL1PPARDPPARA
SCHEMBL734351 0.84 GFER (0.44) ALDH1A1MAPTMAPK1HTTCYP3A4
SCHEMBL734352 0.84 GFER (0.44) ALDH1A1MAPTMAPK1HTTCYP3A4
SCHEMBL734346 0.81 HSD17B10 (0.52) ALDH1A1LMNAMAPTALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 CHRM4 83/4885KCNA5 1926/4885L3MBTL1 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.